Syndax Pharmaceuticals Inc
SNDX · XNASCIK 1395937fmd_00VGBW1GWKZ0J5H2NCG40TBQRBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 48 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 2 | 2 | 2 | 2 | 140 | 0 | 0 | 24 | 172 |
| Research and development | 32 | 48 | 60 | 43 | 50 | 88 | 118 | 163 | 242 | 259 |
| Selling, general and administrative | – | – | – | – | – | 25 | 33 | 67 | 121 | 180 |
| Total operating expenses | 45 | 64 | 77 | 59 | 73 | 113 | 152 | 230 | 363 | 445 |
| Operating income | (44) | (62) | (76) | (58) | (71) | 26 | (152) | (230) | (340) | (273) |
| Interest expense | – | – | – | – | 2 | 2 | 3 | 0 | (0) | 0 |
| Interest and investment income | – | – | 2 | 2 | 1 | 0 | 6 | 21 | 26 | 23 |
| Other non-operating income (expense) | (1) | 1 | 2 | 1 | (2) | (1) | 2 | 21 | 21 | (12) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | 0 |
| Net income | (44) | (61) | (74) | (56) | (73) | 25 | (149) | (209) | (319) | (285) |
| Net income to common shareholders | (47) | (61) | (74) | (56) | (77) | 25 | (149) | (209) | (319) | (285) |